Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) has received a consensus rating of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Free Report) – Research analysts at HC Wainwright raised their Q1 2024 EPS estimates for Deciphera Pharmaceuticals in a report issued on Wednesday, February 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.63) per share for the quarter, up from their previous estimate […]
Deciphera Pharmaceuticals (NASDAQ:DCPH) Trading 6.3% Higher themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Deciphera Pharmaceuticals (NASDAQ:DCPH) Given New $23.00 Price Target at Stifel Nicolaus theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04, Briefing.com reports. The business had revenue of $48.30 million during the quarter, compared to analyst estimates of $45.93 million. Deciphera Pharmaceuticals had a […]